A股異動 | 佐力藥業(300181.SZ)大漲15% 料年度淨利同比增長232.12%-271.2%
格隆匯1月11日丨佐力藥業(300181.SZ)高開高走,現報6.5元創一個月新高,漲幅15.04%,最新總市值39.56億。公司8日公吿稱,預計2020年度歸屬於上市公司股東的淨利潤8500.00萬元-9500.00萬元,同比增長232.12%-271.20%。儘管受到一季度疫情的不利影響,但公司主營產品銷售仍取得了增長,烏靈系列營業收入同比增長24.7%,百令系列營業收入同比增長18.8%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.